Transforming growth factor-βinduced cross talk between p53 and a MicroRNA in the pathogenesis of diabetic nephropathy

Diabetes

Volumn 62, Issue 9, 2013, Pages 3151-3162

  Deshpande, Supriya D ^a   Putta, Sumanth ^a   Wang, Mei ^a   Lai, Jennifer Y ^b   Bitzer, Markus ^b   Nelson, Robert G ^c   Lanting, Linda L ^a   Kato, Mitsuo ^a   Natarajan, Rama ^a  

^a CITY OF HOPE NATIONAL MEDICAL CENTER   (United States)

^b UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^c NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

LOCKED NUCLEIC ACID; MICRORNA 192; PROTEIN P53; TRANSFORMING GROWTH FACTOR BETA; MICRORNA; MIRN192 MICRORNA, MOUSE;

ALBUMINURIA; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DIABETIC NEPHROPATHY; HUMAN; HUMAN TISSUE; IN VITRO STUDY; IN VIVO STUDY; KIDNEY CORTEX; KIDNEY FIBROSIS; KIDNEY HYPERTROPHY; MOUSE; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEINURIA; RANDOMIZED CONTROLLED TRIAL (TOPIC); SIGNAL TRANSDUCTION; TRANSCRIPTION INITIATION; ANIMAL; CELL CULTURE; DNA MICROARRAY; GENETICS; IMMUNOHISTOCHEMISTRY; KNOCKOUT MOUSE; METABOLISM; MOUSE MUTANT; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; WESTERN BLOTTING;

ANIMALS; BLOTTING, WESTERN; CELLS, CULTURED; DIABETIC NEPHROPATHIES; IMMUNOHISTOCHEMISTRY; MICE; MICE, KNOCKOUT; MICE, MUTANT STRAINS; MICRORNAS; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; TRANSFORMING GROWTH FACTOR BETA; TUMOR SUPPRESSOR PROTEIN P53;

EID: 84884793994     PISSN: 00121797     EISSN: 1939327X     Source Type: Journal    
DOI: 10.2337/db13-0305     Document Type: Article

References (49)

1. Ziyadeh FN. The extracellular matrix in diabetic nephropathy. Am J Kidney Dis 1993;22:736-744
2. Steffes MW, Osterby R, Chavers B, Mauer SM. Mesangial expansion as a central mechanism for loss of kidney function in diabetic patients. Diabetes 1989;38:1077-1081
3. Kato M, Park JT, Natarajan R. MicroRNAs and the glomerulus. Exp Cell Res 2012;318:993-1000
4. Declèves AE, Sharma K. New pharmacological treatments for improving renal outcomes in diabetes. Nat Rev Nephrol 2010;6:371-380
5. Kato M, Zhang J, Wang M, et al. MicroRNA-192 in diabetic kidney glomeruli and its function in TGF-beta-induced collagen expression via inhibition of E-box repressors. Proc Natl Acad Sci USA 2007;104:3432-3437
6. Yamamoto T, Nakamura T, Noble NA, Ruoslahti E, Border WA. Expression of transforming growth factor beta is elevated in human and experimental diabetic nephropathy. Proc Natl Acad Sci USA 1993;90:1814-1818
7. Sharma K, Ziyadeh FN, Alzahabi B, et al. Increased renal production of transforming growth factor-beta1 in patients with type II diabetes. Diabetes 1997;46:854-859
8. Kato M, Yuan H, Xu ZG, et al. Role of the Akt/FoxO3a pathway in TGF-beta1-mediated mesangial cell dysfunction: a novel mechanism related to diabetic kidney disease. J Am Soc Nephrol 2006;17:3325-3335
9. Zhou L, Fu P, Huang XR, Liu F, Lai KN, Lan HY. Activation of p53 promotes renal injury in acute aristolochic acid nephropathy. J Am Soc Nephrol 2010;21:31-41
10. Bhatt K, Zhou L, Mi QS, Huang S, She JX, Dong Z. MicroRNA-34a is induced via p53 during cisplatin nephrotoxicity and contributes to cell survival. Mol Med 2010;16:409-416
11. Yang L, Besschetnova TY, Brooks CR, Shah JV, Bonventre JV. Epithelial cell cycle arrest in G2/M mediates kidney fibrosis after injury. Nat Med 2010;16:535-543
12. Samarakoon R, Overstreet JM, Higgins SP, Higgins PJ. TGF-b1 → SMAD/p53/USF2 → PAI-1 transcriptional axis in ureteral obstruction-induced renal fibrosis. Cell Tissue Res 2012;347:117-128
13. Molitoris BA, Dagher PC, Sandoval RM, et al. siRNA targeted to p53 attenuates ischemic and cisplatin-induced acute kidney injury. J Am Soc Nephrol 2009;20:1754-1764
14. Niranjan T, Bielesz B, Gruenwald A, et al. The Notch pathway in podocytes plays a role in the development of glomerular disease. Nat Med 2008;14: 290-298
15. Jung DS, Lee SH, Kwak SJ, et al. Apoptosis occurs differentially according to glomerular size in diabetic kidney disease. Nephrol Dial Transplant 2012;27:259-266
16. Tikoo K, Singh K, Kabra D, Sharma V, Gaikwad A. Change in histone H3 phosphorylation, MAP kinase p38, SIR 2 and p53 expression by resveratrol in preventing streptozotocin induced type I diabetic nephropathy. Free Radic Res 2008;42:397-404
17. Suzuki HI, Miyazono K. Dynamics of microRNA biogenesis: crosstalk between p53 network and microRNA processing pathway. J Mol Med (Berl) 2010;88:1085-1094
18. Kim T, Veronese A, Pichiorri F, et al. p53 regulates epithelial- mesenchymal transition through microRNAs targeting ZEB1 and ZEB2. J Exp Med 2011; 208:875-883
19. Hermeking H. MicroRNAs in the p53 network: micromanagement of tumour suppression. Nat Rev Cancer 2012;12:613-626
20. Pichiorri F, Suh SS, Rocci A, et al. Downregulation of p53-inducible mi-croRNAs 192, 194, and 215 impairs the p53/MDM2 autoregulatory loop in multiple myeloma development. Cancer Cell 2010;18:367-381
21. Bartel DP. MicroRNAs: target recognition and regulatory functions. Cell 2009;136:215-233
22. Mendell JT, Olson EN. MicroRNAs in stress signaling and human disease. Cell 2012;148:1172-1187
23. Natarajan R, Putta S, Kato M. MicroRNAs and diabetic complications. J Cardiovasc Transl Res 2012;5:413-422
24. Kato M, Arce L, Wang M, Putta S, Lanting L, Natarajan R. A microRNA circuit mediates transforming growth factor-b1 autoregulation in renal glomerular mesangial cells. Kidney Int 2011;80:358-368
25. Chung AC, Huang XR, Meng X, Lan HY. miR-192 mediates TGF-beta/Smad3- driven renal fibrosis. J Am Soc Nephrol 2010;21:1317-1325
26. Wang Q, Wang Y, Minto AW, et al. MicroRNA-377 is up-regulated and can lead to increased fibronectin production in diabetic nephropathy. FASEB J 2008;22:4126-4135
27. Wang XX, Jiang T, Shen Y, et al. Diabetic nephropathy is accelerated by farnesoid X receptor deficiency and inhibited by farnesoid X receptor activation in a type 1 diabetes model. Diabetes 2010;59:2916-2927
28. Wang G, Kwan BC, Lai FM, et al. Intrarenal expression of miRNAs in patients with hypertensive nephrosclerosis. Am J Hypertens 2010;23: 78-84
29. Wang G, Kwan BC, Lai FM, et al. Intrarenal expression of microRNAs in patients with IgA nephropathy. Lab Invest 2010;90:98-103
30. Lorenzen JM, Haller H, Thum T. MicroRNAs as mediators and therapeutic targets in chronic kidney disease. Nat Rev Nephrol 2011;7:286-294
31. Long J, Wang Y, Wang W, Chang BH, Danesh FR. MicroRNA-29c is a signature microRNA under high glucose conditions that targets Sprouty ho-molog 1, and its in vivo knockdown prevents progression of diabetic nephropathy. J Biol Chem 2011;286:11837-11848
32. Kato M, Putta S, Wang M, et al. TGF-beta activates Akt kinase through a microRNA-dependent amplifying circuit targeting PTEN. Nat Cell Biol 2009;11:881-889
33. Putta S, Lanting L, Sun G, Lawson G, Kato M, Natarajan R. Inhibiting mi-croRNA-192 ameliorates renal fibrosis in diabetic nephropathy. J Am Soc Nephrol 2012;23:458-469
34. Sun L, Zhang D, Liu F, et al. Low-dose paclitaxel ameliorates fibrosis in the remnant kidney model by down-regulating miR-192. J Pathol 2011;225:364-377
35. Roy B, Beamon J, Balint E, Reisman D. Transactivation of the human p53 tumor suppressor gene by c-Myc/Max contributes to elevated mutant p53 expression in some tumors. Mol Cell Biol 1994;14:7805-7815
36. Weil EJ, Lemley KV, Yee B, et al. Podocyte detachment in type 2 diabetic nephropathy. Am J Nephrol 2011;33(Suppl. 1):21-24
37. Weil EJ, Fufaa G, Jones LI, et al. Effect of losartan on prevention and progression of early diabetic nephropathy in American Indians with type 2 diabetes. Diabetes 2013;62:3224-3231
38. Cohen CD, Frach K, Schlöndorff D, Kretzler M. Quantitative gene expression analysis in renal biopsies: a novel protocol for a high-throughput multicenter application. Kidney Int 2002;61:133-140
39. Lindenmeyer MT, Eichinger F, Sen K, et al. Systematic analysis of a novel human renal glomerulus-enriched gene expression dataset. PLoS ONE 2010;5:e11545
40. Hodgin JB, Nair V, Zhang H, et al. Identification of cross-species shared transcriptional networks of diabetic nephropathy in human and mouse glomeruli. Diabetes 2013;62:299-308
41. Cohen CD, Lindenmeyer MT, Eichinger F, et al. Improved elucidation of biological processes linked to diabetic nephropathy by single probe-based microarray data analysis. PLoS One 2008;3:e2937
42. Pavkov ME, Knowler WC, Hanson RL, Nelson RG. Diabetic nephropathy in American Indians, with a special emphasis on the Pima Indians. Curr Diab Rep 2008;8:486-493
43. Bueno MJ, Malumbres M. MicroRNAs and the cell cycle. Biochim Biophys Acta 2011;1812:592-601
44. Kato MV, Sato H, Nagayoshi M, Ikawa Y. Upregulation of the elongation factor-1alpha gene by p53 in association with death of an erythroleukemic cell line. Blood 1997;90:1373-1378
45. El Mesallamy HO, Ahmed HH, Bassyouni AA, Ahmed AS. Clinical significance of inflammatory and fibrogenic cytokines in diabetic nephropathy. Clin Biochem 2012;45:646-650
46. Krupa A, Jenkins R, Luo DD, Lewis A, Phillips A, Fraser D. Loss of MicroRNA-192 promotes fibrogenesis in diabetic nephropathy. J Am Soc Nephrol 2010;21:438-447
47. Kasinath BS, Feliers D. The complex world of kidney microRNAs. Kidney Int 2011;80:334-337
48. Jenkins RH, Martin J, Phillips AO, Bowen T, Fraser DJ. Transforming growth factor b1 represses proximal tubular cell microRNA-192 expression through decreased hepatocyte nuclear factor DNA binding. Biochem J 2012;443:407-416
49. Wang B, Herman-Edelstein M, Koh P, et al. E-cadherin expression is regulated by miR-192/215 by a mechanism that is independent of the profibrotic effects of transforming growth factor-beta. Diabetes 2010;59:1794-1802